Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Measured by its ability to neutralize VEGF R2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 10-50 ng/mL in the presence of 50 ng/mL Recombinant Human VEGF R2/KDR/Flk‑1 Fc Chimera and 5 ng/mL Recombinant Human VEGF165.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Detection of VEGF R2/KDR/Flk‑1 in HUVEC Human Cells by Flow Cytometry.
HUVEC human umbilical vein endothelial cells were stained with Mouse Anti-Human VEGF R2/KDR/Flk‑1 Monoclonal Antibody (Catalog # MAB3572, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).
VEGF R2/KDR Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Human VEGF R2/KDR Antibody.
Recombinant Human VEGF R2/KDR Fc Chimera (Catalog # 357-KD) inhibits Recombinant Human VEGF165 (Catalog # 293-VE) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human VEGF165 (5 ng/mL) activity elicited by Recombinant Human VEGF R2/KDR Fc Chimera (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human VEGF R2/KDR Monoclonal Antibody (Catalog # MAB3572). The ND50 is typically 10-50 ng/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGF R2/KDR/Flk-1
VEGF R2 (KDR/Flk-1), VEGF R1 (Flt-1) and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mature VEGF R2 is composed of a 745 aa extracellular domain, a 25 aa transmembrane domain and a 567 aa cytoplasmic domain. In contrast to VEGF R1 which binds both PlGF and VEGF with high affinity, VEGF R2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGF R2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.
Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you
include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image.
Limited to verified customers in USA, Canada and Europe.
Read what people are saying who have used Human VEGF R2/KDR/Flk-1 Antibody.
We have 1 review tested in 1 species: Human.
We have 1 review tested in 1 application: ELISA.